The oral estrogen receptor PROTAC, ARV-471, shows more robust tumor growth inhibition and ERα degradation compared to fulvestrant in an orthotopic MCF7/estradiol xenograft model, and inhibits growth of tamoxifen-resistant tumors while also reducing tumor ERa levels. This evidence concerns the gene ESR1 and neoplasm.